Kronos Bio Inc (NAS:KRON)
$ 0.9917 -0.0183 (-1.81%) Market Cap: 59.59 Mil Enterprise Value: -63.27 Mil PE Ratio: 0 PB Ratio: 0.43 GF Score: 32/100

Kronos Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 03:20PM GMT
Release Date Price: $26.86 (-2.43%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good morning, everyone. Thanks for joining us. I'm Andrea Tan, biotech analyst at Goldman Sachs, and we're pleased to have with us this morning the team from Kronos. Norbert Bischofberger, President; Yasir Al-Wakeel, CFO; Jorge DiMartino, CMO; and Chris Dinsmore, CSO.

Questions & Answers

Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

With that, Norbert, maybe I'll turn it over to you. And we'd love to hear about the Kronos story, how the company has been evolving as you come up on 1 year almost as a public company?

Norbert W. Bischofberger
Kronos Bio, Inc. - President, CEO & Director

Thanks, Andrea. And also thanks to Goldman Sachs for having us here today. It's a great pleasure. So Andrea, we were founded only 3 years ago. It's actually amazing, but we have made just incredible progress in these 3 years. We're focused on transcription factors and their associated transcriptional regulatory

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot